• Company
• Protein C deficiency drug 'Ceprotin' begins negotiations
• by Eo, Yun-Ho Jul 12, 2024 05:48am

• Company
• Will Epkinly become a game-changer in the blood cancer mkt?
• by Hwang, Byung-woo Jul 12, 2024 05:47am

• Company
• "Enhertu gets expanded indication to treat lung cancer"
• by Son, Hyung-Min Jul 11, 2024 06:12am

• Company
• Will Trodelvy be deliberated for reimb by DREC in August?
• by Eo, Yun-Ho Jul 11, 2024 05:47am

• Company
• From obesity to brain diseases...expansion of GLP-1 agonists
• by Son, Hyung-Min Jul 11, 2024 05:46am

• Company
• GC Biopharma ships first batch of ‘Alyglo’ to the U.S.
• by Son, Hyung-Min Jul 10, 2024 05:48am

• Company
• Tecentriq reapplies for reimb in early stage NSCLC
• by Eo, Yun-Ho Jul 10, 2024 05:48am

• Company
• With Lixiana and Enhertu, Daiichi-Sankyo’s sales growth↑
• by Hwang, Byung-woo Jul 9, 2024 06:07am

• Company
• Industry struggles to develop new atopic dermatitis drugs
• by Son, Hyung-Min Jul 9, 2024 05:51am

• Company
• Takeda seeks top-line growth to KRW 300 billion
• by Hwang, Byung-woo Jul 9, 2024 05:51am